Next Article in Journal
Anionic Polyelectrolyte Hydrogel as an Adjuvant for Vaccine Development
Previous Article in Journal
Ligand-Based and Structured-Based In Silico Repurposing Approaches to Predict Inhibitors of SARS-CoV-2 Mpro Protein
Open AccessReview

The Potential Benefit of Beta-Blockers for the Management of COVID-19 Protocol Therapy-Induced QT Prolongation: A Literature Review

1
Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Syiah Kuala, Banda Aceh, Aceh 2311, Indonesia
2
Master Program in Biomedical Science, Faculty of Medicine, University of Brawijaya, Malang 65145, Indonesia
3
Department of Basic Nursing Science, Faculty of Medicine, University of Brawijaya, Malang 65145, Indonesia
*
Author to whom correspondence should be addressed.
Received: 20 September 2020 / Revised: 5 November 2020 / Accepted: 6 November 2020 / Published: 23 November 2020
The World Health Organization (WHO) officially announced coronavirus disease 2019 (COVID-19) as a pandemic in March 2020. Unfortunately, there are still no approved drugs for either the treatment or the prevention of COVID-19. Many studies have focused on repurposing established antimalarial therapies, especially those that showed prior efficacy against Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV), such as chloroquine and hydroxychloroquine, against COVID-19 combined with azithromycin. These classes of drugs potentially induce prolongation of the QT interval, which might lead to lethal arrhythmia. Beta-blockers, as a β-adrenergic receptor (β-AR) antagonist, can prevent an increase in the sympathetic tone, which is the most important arrhythmia trigger. In this literature review, we aimed to find the effect of administering azithromycin, chloroquine, and hydroxychloroquine on cardiac rhythm disorders and our findings show that bisoprolol, as a cardio-selective beta-blocker, is effective for the management of the QT (i.e., the start of the Q wave to the end of the T wave) interval prolongation in COVID-19 patients. View Full-Text
Keywords: COVID-19; beta-blockers; QT prolongation COVID-19; beta-blockers; QT prolongation
Show Figures

Figure 1

MDPI and ACS Style

Heriansyah, T.; Nur Chomsy, I.; Febrianda, L.; Farahiya Hadi, T.; Andri Wihastuti, T. The Potential Benefit of Beta-Blockers for the Management of COVID-19 Protocol Therapy-Induced QT Prolongation: A Literature Review. Sci. Pharm. 2020, 88, 55. https://0-doi-org.brum.beds.ac.uk/10.3390/scipharm88040055

AMA Style

Heriansyah T, Nur Chomsy I, Febrianda L, Farahiya Hadi T, Andri Wihastuti T. The Potential Benefit of Beta-Blockers for the Management of COVID-19 Protocol Therapy-Induced QT Prolongation: A Literature Review. Scientia Pharmaceutica. 2020; 88(4):55. https://0-doi-org.brum.beds.ac.uk/10.3390/scipharm88040055

Chicago/Turabian Style

Heriansyah, Teuku; Nur Chomsy, Indah; Febrianda, Lyra; Farahiya Hadi, Tjut; Andri Wihastuti, Titin. 2020. "The Potential Benefit of Beta-Blockers for the Management of COVID-19 Protocol Therapy-Induced QT Prolongation: A Literature Review" Sci. Pharm. 88, no. 4: 55. https://0-doi-org.brum.beds.ac.uk/10.3390/scipharm88040055

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop